Loading...
•
Sep 30, 2022
Arrowhead Pharmaceuticals Q4 2022 Earnings Report
Announced financial results for the fiscal year ended September 30, 2022.
Key Takeaways
Arrowhead Pharmaceuticals reported its fiscal year results, highlighting revenue and operating expenses. The company strengthened its balance sheet with the sale of Arrowhead’s royalty interest in olpasiran to Royalty Pharma.
Presented interim data on the cardiometabolic pipeline at the American Heart Association (AHA) Scientific Sessions 2022.
Reached full enrollment for Phase 2 studies of cardiometabolic candidates ARO-APOC3 and ARO-ANG3.
Strengthened the balance sheet with the sale of Arrowhead’s royalty interest in olpasiran to Royalty Pharma for $250 million upfront and up to $160 million in milestone payments.
Initiated Phase 1/2a clinical studies for two new investigational medicines designed to treat various muco-obstructive and inflammatory pulmonary conditions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...